About Grace Therapeutics, Inc. - Common Stock (GRCE)
Grace Therapeutics, Inc. is a biotechnology company focused on the development of innovative therapies aimed at treating a range of serious medical conditions. The company specializes in creating novel drug formulations and delivery systems, leveraging advanced technologies to enhance the effectiveness and safety of its therapeutic solutions. By prioritizing patient-centric approaches, Grace Therapeutics seeks to address unmet medical needs and improve outcomes for patients through precision medicine and targeted treatments. The company's commitment to research and collaboration drives its efforts in bringing transformative therapies to market. Read More
NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Grace Therapeutics, Inc. (“Grace” or the “Company”) (NASDAQ: GRCE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
BEDMINSTER, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) today announced the appointment of biotech industry veterans Keith Murphy and Edward Neugeboren to its Board of Directors as independent members, effective March 11, 2025 (the “Effective Date”). In addition, Matthew Wikler, M.D., and Natasha Giordano stepped down from the Board on the Effective Date.
Grace Therapeutics' GTx-104 met its Phase 3 trial endpoint, showing clinical benefits over oral nimodipine. US NDA submission is expected in early 2025.
